Upstream Ventures

Upstream Bio is a clinical-stage biotechnology company dedicated to developing novel therapies for inflammation and immune-mediated diseases. The company's lead asset, vereirumab (UPB-101), is a monoclonal antibody that targets the thymic stromal lymphopoietin receptor (TSLPR), a validated target that sits at the head of the inflammatory cascade. By inhibiting TSLP signaling, Upstream Bio aims to provide more effective and durable treatment options for patients suffering from severe respiratory and inflammatory conditions. The company is currently advancing vereirumab through Phase 2 clinical trials for severe asthma and chronic rhinosinusitis with nasal polyps, while exploring additional indications such as COPD.